bse-closes-points-76-26-up-on-jan-27

BSE closes points 76.26 up on Jan 27

New Delhi, Jan 27 (ANI): Trading at the Bombay Stock Exchange today closed 76.26 points up to stand at 29,355.10. At the National Stock Exchange the Nifty closed 16.15 points up to stand at 8,851.75. JETAIRWAYS and EDELWEISS were among the top gainers of Group A with an increase of 14.74% and 10.25% along with SPARC and MAX with an increase of 10.00% and 9.34% respectively, while the top losers of Group A include GSFC and FSL with a decrease of 11.94% and 7.09% along with UNION BANK and GRUH with a decrease of 5.45% and 5.04% at the close of the markets. The Auto sector is up 265.19 points at 20,371.97. The Indian currency is up 0.22% at Rs 61.46 per dollar. Jan 27, 2015
business-leaders-look-for-better-opportunities-as-india-us-ceo-forum-meet-begins

Business leaders look for better opportunities as India-US CEO forum meet begins

New Delhi, Jan 26 (ANI): Business leaders looked forward to better opportunities as the India-US CEO forum meet began at the Taj Palace Hotel in New Delhi on Monday. Godrej Group Chairman Adi Godrej said that the level of mutual investment & trade will rise tremendously between the two countries. Xpro India Chairman Siddharth Birla said that the communication between the two countries is a clearing logjam. HSBC Chief Naina Lal Kidwai said that the chemistry created by the top leaders between the two countries should be followed at the business level. India-US CEO forum meet is being attended by US President Barack Obama and Prime Minister Narendra Modi. Barack Obama and Narendra Modi will be interacting with dozens of executives from American and Indian companies. Jan 26, 2015
Biocon claims to take Syngene unit public by selling stake

Biocon claims to take Syngene unit public by selling stake

Bengaluru, Jan 23 (ANI): Biocon Ltd would list its research services business arm Syngene by selling up to 15 percent stake in a public offer, the company said, after reporting third-quarter earnings on Friday (January 23). Biocon had previously said it planned to list Syngene but had not given a timeline. Late on Thursday (January 22), it said its board had approved starting the process of listing and hiring merchant bankers to sell 10-15 percent from Biocon's majority stake in the unit in the public offer. Separately, Biocon agreed with Gilead Sciences Inc to licence its chronic hepatitis-C product range, it said in a statement. Jan 23, 2015
MOST POPULAR